• About Us
    • Contact Us
    • Login
    • ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
About Us Contact Us Login ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
Grand Rounds

Does Digital Breast Tomosynthesis Reduce the Number of False Positives Compared to Mammography?

image_pdfFavoriteLoadingFavorite

BACKGROUND AND PURPOSE:

  • Ho et al. (JAMA Network Open, 2022) compared false positive results with digital breast tomosynthesis (3-dimensional mammography) vs digital mammography

METHODS:

  • Prospective observational comparative effectiveness study
    • 126 breast imaging facilities participating in 6 US registries
  • Population
    • 40 to 79 years
    • Screening examinations performed between January 2005 and December 2018
  • Exposures
    • Digital breast tomosynthesis
    • Digital mammography
  • Study design
    • Following exam characteristics were also noted
      • Screening interval
      • Age
      • BIRADS breast density
  • Primary outcomes
    • After 10 years of annual or biennial screening, cumulative risk of ≥1 false positive leading to
      • Recall for further imaging
      • Short-interval follow-up recommendation
      • Biopsy recommendation

RESULTS:

  • 903,495 women | 2,969,055 nonbaseline screening examinations | 699 radiologists
    • Mean age at screening was 57.6 years
    • <60 years: 58%
    • Dense breasts: 46%
    • Use of tomosynthesis: 15%

Annual Screening

  • Cumulative probability of at least 1 false positive result was significantly lower with tomosynthesis vs digital mammography
    • Recall for further imaging
      • Tomosynthesis: 49.6%
      • Mammography: 56.3%
      • Difference –6.7 (95% CI, –7.4 to –6.1)
    • Short interval follow-up recommendation
      • Tomosynthesis: 16.6%
      • Mammography: 17.8%
      • Difference –1.1 (95% CI, –1.7 to –0.6)
    • Biopsy recommendation
      • Tomosynthesis: 11.2%
      • Mammography: 11.7%
      • Difference –0.5 (95% CI, –1.0 to –0.1)

Biennial Screening

  • Cumulative probability of a false-positive recall was significantly lower for tomosynthesis vs digital mammography
    • Tomosynthesis: 35.7%
    • Mammography: 38.1%
    • Difference –2.4 (95% CI, –3.4 to –1.5)
  • No difference for
    • Short-interval follow-up recommendation
    • Biopsy recommendation

Breast Density

  • Decreases in cumulative probabilities of false-positive results with tomosynthesis vs digital mammography and were largest for annual screening in women with nondense breasts

Other Factors Associated with Lower False Positive Results

  • Biennial vs annual screening (overall)
  • Older vs younger age groups (70 to 79 years vs 40 to 49 years)
  • Entirely fatty vs extremely dense breasts

CONCLUSION:

  • The 10-year cumulative probabilities of false positive breast cancer screening exams were reduced with use of digital breast tomosynthesis vs digital mammography
  • Regardless of screening modality, the following were associated with larger reductions in false positive probabilities
    • Biennial screening interval
    • Older age
    • Nondense breasts
  • The authors state

In this comparative effectiveness study, 10-year cumulative probabilities of false-positive results were lower on digital breast tomosynthesis vs digital mammography

Biennial screening interval, older age, and nondense breasts were associated with larger reductions in false-positive probabilities than screening modality

Learn More – Primary Sources:

Cumulative Probability of False-Positive Results After 10 Years of Screening With Digital Breast Tomosynthesis vs Digital Mammography

Want to stay on top of key guidelines and research papers?

ObGFirst® – Try It Free! »

image_pdfFavoriteLoadingFavorite
< Previous
All Grand Rounds Posts
Next >

Related ObG Topics:

Can AI Algorithms Accurately Diagnose Breast Cancer?
UK Age RCT Final Results: Breast Cancer Screening Beginning at Age 40 with 23 Years Follow-Up
Mammography or Improved Treatment: Which is More Strongly Associated with a Decline in Breast Cancer Mortality?

Sections

  • COVID-19
  • Alerts
  • OB
  • GYN
    • GYN
    • Sexual Health
  • 2T US Atlas
  • The Genome
  • Primary Care
  • Your Practice
  • Grand Rounds
  • My Bookshelf
  • Now@ObG
  • Media

Are you an
ObG Insider?

Get specially curated clinical summaries delivered to your inbox every week for free

  • Site Map/
  • © ObG Project/
  • Terms and Conditions/
  • Privacy/
  • Contact Us/
© ObG Project
SSL Certificate


  • Already an ObGFirst Member?
    Welcome back

    Log In

    Want to sign up?
    Get guideline notifications
    CME Included

    Sign Up

Get Guideline Alerts Direct to Your Phone
Try ObGFirst Free!

Sign In

Lost your password?

Sign Up for ObGFirst and Stay Ahead

  • - Professional guideline notifications
  • - Daily summary of a clinically relevant
    research paper
  • - Includes 1 hour of CME every month

ObGFirst Free Trial

Already a Member of ObGFirst®?

Please log in to ObGFirst to access the 2T US Atlas

Password Trouble?

Not an ObGFirst® Member Yet?

  • - Access 2T US Atlas
  • - Guideline notifications
  • - Daily research paper summaries
  • - And lots more!
ObGFirst Free Trial

Media - Internet

Computer System Requirements

OBG Project CME requires a modern web browser (Internet Explorer 10+, Mozilla Firefox, Apple Safari, Google Chrome, Microsoft Edge). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, or Real Networks Real One Player.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information
presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Jointly provided by

NOT ENOUGH CME HOURS

It appears you don't have enough CME Hours to take this Post-Test. Feel free to buy additional CME hours or upgrade your current CME subscription plan

Subscribe

JOIN OBGFIRST AND GET CME/CE CREDITS

One of the benefits of an ObGFirst subscription is the ability to earn CME/CE credits from the ObG entries you read. Tap the button to learn more about ObGFirst

Learn More
Leaving ObG Website

You are now leaving the ObG website and on your way to PRIORITY at UCSF, an independent website. Therefore, we are not responsible for the content or availability of this site